Subscribe
Share
Share
Embed
Most heartburn that persists on a PPI is not refractory acid reflux, so this episode treats that label as a diagnosis to be tested. The workup starts with how the drug is taken, then intensifies acid suppression, then adds endoscopy with biopsies and the reflux test that fits the patient, read as one of four diagnoses. It then covers medical options for proven reflux that persists and the need for objective testing in extraesophageal symptoms. The second half turns to antireflux surgery: proof of reflux first, the three-test workup, what a wrap rebuilds, matching the wrap to motility, the magnetic ring and transoral options, and the effect of weight.
Topics covered
Key decisions
This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.
For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.
Questions or feedback: hello@boardpearls.com.
The most complete gastroenterology board-review podcast on the web, and it is entirely free. This is the GI series from Board Pearls: board review built around clinical reasoning, not recall. Every episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards. No trivia, no textbook dictation, just the thinking that earns the point.
Over 100 episodes span the full blueprint across nine modules (esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics), grouped by chapter and built from the guidelines and pivotal trials the boards are written from: ACG, AGA, AASLD, and ASGE.
Pair it with the written curriculum, question bank, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode two of three of the GERD and Refractory Reflux chapter, in the Esophageal Disorders module. This episode covers two decisions: what to do when heartburn continues despite a proton pump inhibitor, PPI, and who should have antireflux surgery. Most patients with heartburn on a PPI don't have refractory acid reflux at all: when referred patients are worked up step by step, only about a fifth turn out to have truly refractory reflux-related heartburn. A forty-four-year-old woman labeled refractory teaches the workup in order: checking how she takes the drug, intensifying it, endoscopy with biopsies, the reflux test that fits her, and reading the result as one of four diagnoses, each treated differently. A man with proven reflux that persists on a PPI teaches the medical options aimed at the mechanism. A fifty-eight-year-old man with chronic cough teaches why extraesophageal symptoms need objective testing. And a forty-seven-year-old man who wants an operation teaches what has to be proven first, which three tests make up the workup, what a wrap rebuilds, and how motility, hernia size, and weight choose the procedure.
Here's the first patient. A forty-four-year-old woman has had heartburn for two years. Her doctor started omeprazole twenty milligrams daily a year ago and doubled it when it didn't help. She still has burning behind her breastbone most days. She's never had an endoscopy. She isn't overweight. She has no dysphagia, weight loss, or bleeding. She's been told she has refractory reflux and asks whether she needs surgery.
She has persistent heartburn on a PPI. Refractory reflux is defined by persistent symptoms on optimized acid suppression, so before that label is accepted, the first step is to question the diagnosis, starting with how she takes the drug. It's the cheapest step and the one most often skipped, so she's asked exactly how and when she takes it. She takes it at bedtime, with a glass of water.
That explains a lot. A PPI is a prodrug that binds only proton pumps that are actively secreting, and the most pumps are active when a meal stimulates acid secretion. Its half-life in the blood is about ninety minutes. Taken at bedtime with no meal to follow, it's gone before most pumps switch on. Patients who take a PPI at bedtime, with food, or without timing instructions are functionally untreated, and she's been functionally untreated for a year. Doubling a dose taken at the wrong time doesn't fix that.
So she's taught the timing: thirty to sixty minutes before breakfast, and before dinner when it's twice daily. About one in eight patients referred for refractory reflux gets better with nothing more than a structured PPI trial with explicit meal-timing instructions, which is why timing is checked before anything is escalated.
If correct timing isn't enough, the next step is to intensify treatment properly. A twice-daily PPI before breakfast and dinner covers both meal-driven waves of pump activation. A more potent PPI, rabeprazole or esomeprazole rather than pantoprazole, uses the real differences in strength among them. Vonoprazan, a potassium-competitive acid blocker, binds active and inactive pumps alike, has a half-life of seven to nine hours, and doesn't depend on meal timing, so it gives more complete and sustained acid suppression than any PPI dose; it's the modern answer for true breakthrough acid on a twice-daily PPI. And for documented acid breakthrough at night on a twice-daily PPI, a bedtime histamine two receptor blocker can be added, though tachyphylaxis means its effect fades.
She takes omeprazole correctly, before breakfast and dinner, for eight weeks, and the burning continues. Correctly timed, twice-daily treatment has failed, so she has an endoscopy, and it would be done even if a previous endoscopy had been normal. Its most important job here is biopsies, from two levels of the esophagus, proximal and distal, two to four from each, because eosinophilic esophagitis is a recognized cause of PPI failure, it looks normal at endoscopy in a meaningful minority of patients, and it's missed without biopsies. The endoscopy also looks for erosive esophagitis and Barrett esophagus, measures any hiatal hernia, and excludes other structural disease. Her endoscopy is normal, and the biopsies show no eosinophilic esophagitis.
With a normal endoscopy, her reflux has to be measured, and which test she gets turns on one fact: has reflux disease ever been objectively proven? Under the Lyon consensus, updated to version two in twenty twenty-four, definitive evidence includes Los Angeles grade B, C, or D esophagitis, long-segment Barrett esophagus, a peptic stricture, and an abnormal prior pH study.
Reflux has never been proven in her, so she's tested off PPI, because the question is whether she has reflux disease at all, and acid suppression would hide the answer. She stops the PPI for seven days, and during an endoscopy a wireless pH capsule is clipped to the esophagus six centimeters above the squamocolumnar junction. It records esophageal pH for forty-eight to ninety-six hours. The longer recording is more likely to capture the days she has symptoms, and the results are more reproducible. Its limitations are that it measures acid only, so it misses non-acid reflux, and it doesn't measure gastric pH. It's the preferred test for a patient like her, with intermittent typical symptoms, tested off PPI to establish the diagnosis.
If reflux had already been proven, the question would be why symptoms continue despite treatment, and the test would be done on PPI, with a twenty-four-hour catheter that measures both pH and impedance. Impedance detects reflux whether or not it's acidic, which matters when acid is suppressed, and a separate sensor measures gastric pH. That study is preferred for a patient on PPI whose frequent symptoms, including atypical ones, need to be attributed to acid reflux, non-acid reflux, or neither. So the rule is off PPI to find out whether reflux exists, and on PPI with impedance to find out why proven reflux still causes symptoms.
Her study is read under the Lyon consensus, and two things are read. The first is acid exposure time: the percentage of the recording with esophageal pH below four. Over six percent, on at least two days of a wireless study, is definitive reflux disease. Under four percent on each day is strong evidence against it. Four to six percent is borderline and needs supporting evidence: more than eighty reflux episodes in twenty-four hours, a positive symptom association, a low mean nocturnal baseline impedance under fifteen hundred ohms, which is a sign of lining damaged by reflux, or an abnormal post-reflux swallow-induced peristaltic wave index. A baseline impedance over twenty-five hundred ohms argues against reflux disease.
The second is whether her symptoms line up with reflux events. She presses a button whenever she feels the burning. The symptom index is the percentage of her symptom episodes preceded by a reflux event, positive at fifty percent or more. The symptom association probability applies a Fisher exact test to time intervals classified by whether a symptom and a reflux event occurred, and it's positive at ninety-five percent or more. The two measures overlap but capture different aspects of association, and the probability is the more rigorous statistically.
Those two readings give one of four diagnoses, each with its own treatment. Acid exposure over six percent is confirmed reflux disease, whatever the symptom association shows; if it persists on maximal medical therapy, that's true refractory reflux. Four to six percent with supporting evidence is borderline reflux disease, and treatment is individualized.
The two diagnoses with normal acid exposure are the ones most often mistaken for refractory reflux. Under four percent with a positive symptom association is reflux hypersensitivity. The amount of reflux is normal, but the esophagus registers ordinary, physiologic reflux events as pain. Treatment combines acid suppression with a neuromodulator, because the reflux events are real triggers but the problem is the sensitivity. Under four percent with a negative symptom association is functional heartburn. The burning isn't related to reflux events at all. Treatment is a neuromodulator, such as a low-dose tricyclic, a selective serotonin reuptake inhibitor, SSRI, or hypnotherapy, without more acid suppression, and never surgery, because neither a higher PPI dose nor a fundoplication helps heartburn that reflux doesn't cause.
Her study shows an acid exposure time of two percent on every day, and her symptoms don't line up with reflux events. She has functional heartburn. So her PPI is stopped, she starts a low-dose tricyclic such as amitriptyline, twenty-five to fifty milligrams at bedtime, and her question gets a clear answer: no, she doesn't need surgery, and surgery would make her worse.
Before settling on any of these diagnoses, the conditions that imitate refractory reflux are looked for, because each needs entirely different treatment. Rumination syndrome is the effortless regurgitation of recognizable food within minutes of eating, and manometry with impedance shows a characteristic pressure spike called an R wave; it's treated with diaphragmatic breathing, not acid suppression or surgery. Supragastric belching is air swallowed rapidly into the esophagus and expelled before it reaches the stomach, often perceived as reflux; impedance shows air moving in and out without reaching the stomach, and it's treated with speech and behavioral therapy. Achalasia can present as regurgitation and heartburn from retained food and saliva fermenting above a sphincter that won't relax, so high-resolution manometry read with the Chicago classification is part of any workup that heads toward surgery.
The second patient is the one who really does have refractory reflux. A man has reflux proven by grade C esophagitis. On an impedance study on his PPI, he still has abnormal reflux, much of it weakly acidic, and regurgitation is his main complaint. Medical options aimed at the mechanism come first. Baclofen, ten milligrams three times a day, is a gamma-aminobutyric acid type B, GABA-B, agonist that suppresses transient lower esophageal sphincter relaxations, which reduces both acid and non-acid reflux events and helps regurgitation; drowsiness and fatigue limit it, so it's generally kept for short-term add-on use. An alginate after meals forms a gel raft on contact with gastric acid that floats on the stomach contents and pushes the post-meal acid pocket away from the junction, removing the material for the next sphincter relaxation. It helps breakthrough symptoms after meals and works as an add-on to a PPI in non-erosive disease.
Two other agents have narrower roles. Sucralfate, a sulfated sucrose and aluminum complex, binds ulcerated mucosa and coats it; its evidence outside pregnancy is limited, but it's the preferred agent in pregnancy. Antacids, such as calcium carbonate, magnesium hydroxide, and aluminum hydroxide combinations, give quick relief on demand but heal nothing and aren't maintenance therapy. If his regurgitation persists on these, he's the kind of patient who does well with surgery.
The third patient shows why some symptoms need extra caution. A fifty-eight-year-old man has a year of chronic cough with a normal chest x-ray, and a laryngoscopy said to show reflux changes. Extraesophageal symptoms, such as chronic cough, laryngitis, asthma, and dental erosion, respond to a PPI much less than heartburn does, and pH testing is positive in only a minority of these patients. At least one of the laryngeal findings traditionally attributed to reflux appears in eighty-six percent of healthy volunteers, so laryngoscopy overdiagnoses reflux. Cough due to proven acid reflux improves with a PPI in about half of patients, and far fewer improve when reflux hasn't been confirmed. So he needs objective reflux testing before he's committed to a long-term PPI. And if he ever considered surgery, fundoplication does worse for cough, hoarseness, and asthma than for typical heartburn and regurgitation, with more than twice the hazard of symptoms returning, so extraesophageal symptoms alone are a weak reason to operate.
The fourth patient is a surgical candidate, and his case starts with the rule that the first patient made necessary. A forty-seven-year-old man has had reflux for eight years. A PPI before breakfast controls his heartburn well. What it doesn't control is regurgitation: sour fluid coming up into his mouth when he bends over or lies down, several times a week, sometimes waking him coughing. He'd rather not take a pill for the next forty years. His body mass index is twenty-nine. He asks whether he should have surgery.
Whether he qualifies depends on one rule that comes before anything else. No one has an antireflux procedure without objective proof of reflux: Los Angeles grade B or worse esophagitis, long-segment Barrett esophagus, a peptic stricture, or an abnormal pH study off PPI. Failing a PPI is not an indication by itself. Most patients who fail a PPI don't have refractory reflux. They have a timing problem, functional heartburn, reflux hypersensitivity, eosinophilic esophagitis, a motility disorder, or a behavioral disorder, and an operation can't help symptoms that reflux doesn't cause.
The evidence for that rule comes from a randomized trial of carefully selected patients with truly refractory reflux-related heartburn, drawn from several hundred refractory referrals. Laparoscopic Nissen fundoplication was compared with active medical therapy of omeprazole, baclofen, and desipramine, and with placebo medical therapy. Surgery succeeded in about two thirds at one year, more than either medical arm. But only the small selected subgroup reached randomization, so surgery wins only in patients who have been through the workup, and empiric surgery for PPI failure without it will fail.
His main complaint, regurgitation, works in his favor, because surgery's advantage over medicine lies largely in regurgitation control. To prove his reflux and choose his procedure, every antireflux procedure needs the same three tests, because each decides something the others can't.
Endoscopy grades any esophagitis, looks for Barrett esophagus, eosinophilic esophagitis, and cancer, and measures the hiatal hernia in centimeters. The hernia size must be in the report, because it decides which procedures are possible. The endoscopist can also grade the flap valve at the junction under the American Foregut Society classification, viewed from inside the stomach looking back up. Grade one is an intact, snug, omega-shaped valve with no hernia. Grade two is no hernia but an opening widened up to two centimeters with a flattened valve, already abnormal. Grade three is a small hernia up to two centimeters with an opening up to three and no valve. Grade four is a large hernia with a wide-open junction and no valve. That grade helps choose between surgical and endoscopic options. His endoscopy, done on his PPI, shows healed mucosa and a two-and-a-half-centimeter sliding hernia.
High-resolution manometry does two jobs. It confirms normal peristalsis, which a full wrap requires, or finds weak motility, which calls for a partial wrap. And it excludes achalasia, whose regurgitation of fermenting food can pass for reflux, and in which a fundoplication would be a disaster, because it tightens a sphincter that already won't open. His manometry is normal.
A pH study off PPI is needed whenever reflux hasn't already been proven. His endoscopy was on a PPI and showed no esophagitis, so there's no objective proof yet. He stops his PPI for seven days and has the study. His acid exposure time is nine percent, and his regurgitation episodes match reflux events. His reflux is proven, and he qualifies.
Choosing among operations starts with what an operation rebuilds, because that explains both its benefits and its costs. Every fundoplication brings a segment of esophagus back down into the abdomen, reduces the hernia, closes the gap in the diaphragm by bringing the crura together, and wraps part of the gastric fundus around the lower esophagus. That restores three parts of the normal barrier: the angle of His between esophagus and stomach, which works as a flap valve, the abdominal pressure on the lower esophagus, and the crural diaphragm's support of the sphincter. The wrap also acts as a one-way valve, and it keeps the fundus from distending in the way that triggers transient sphincter relaxations. That one-way valve is also the source of the costs: a wrap that keeps acid down can also keep food from getting through and gas from getting out.
His manometry decides which wrap. A Nissen fundoplication is a full, three-hundred-sixty-degree posterior wrap. It gives the best reflux control, so it's the operation of choice with normal peristalsis. Its costs are dysphagia after surgery and gas-bloat syndrome, the inability to vent the stomach during a normal sphincter relaxation. It's contraindicated in scleroderma and other states with absent contractions, because an esophagus without peristalsis can't push food past a tight wrap.
A Toupet fundoplication is a partial, two-hundred-seventy-degree posterior wrap, leaving the front third of the lower esophagus uncovered. It controls reflux slightly less well, but it obstructs a weak peristaltic wave much less, so it's the operation for hypomotility, including scleroderma and ineffective esophageal motility, if they have any wrap at all. In patients with normal motility, the difference in reflux control is modest. In patients with weak motility, it's the difference between a working wrap and severe dysphagia. A Dor fundoplication is a partial, one-hundred-eighty-degree anterior wrap, mainly paired with a Heller myotomy for achalasia, giving some reflux protection without compromising a sphincter that was deliberately cut. It has a smaller role as a primary reflux operation.
Surgery isn't better than medicine for everyone, and he's told that. In patients who respond to a PPI, a randomized comparison found that long-term PPI kept reflux in remission over five years at least as well as fundoplication. So a PPI responder isn't told surgery is the better treatment. Surgery's real advantages are control of regurgitation, which acid suppression doesn't stop, and freedom from lifelong medication for patients who can't tolerate it or don't want it. Those are his reasons.
He's also told the risks. Laparoscopic fundoplication is safe: mortality in modern series is under a tenth of a percent, and complications within thirty days occur in about four percent. But ten to thirty percent of patients are back on antireflux medication within five years, with female sex, older age, and other illnesses predicting recurrence. The complications after surgery are a tight wrap, a slipped wrap, telescoping, and gas-bloat. When a wrap seems to fail, the first test is a barium swallow rather than an endoscope, because it shows the shape of the repair.
His hernia size and preference open two less invasive options, and each has strict selection rules. Magnetic sphincter augmentation places a ring of titanium beads with magnetic cores around the lower esophagus laparoscopically. The magnets are strong enough to hold the junction closed against the normal pressure swings between abdomen and chest, but weak enough that a swallowed bolus pushes the beads apart. It preserves the ability to belch and vomit, its main advantage over a Nissen, and it can be removed. It's for selected patients with objectively confirmed reflux who fail or can't tolerate medical therapy, and the American College of Gastroenterology recommends considering it as an alternative to fundoplication specifically for troublesome regurgitation that fails medical therapy, because randomized data show it beats medical therapy for regurgitation. It's excluded by a hiatal hernia larger than three centimeters, a body mass index over thirty-five, Barrett esophagus, grade C or D esophagitis, absent or severely impaired motility, a titanium or nickel allergy, and prior major upper gastrointestinal surgery.
Transoral incisionless fundoplication builds a partial wrap through the mouth, with an endoscopic device that fastens the fundus to the lower esophagus by plication. It avoids skin incisions, but its criteria are tighter: a hiatal hernia under two centimeters, no grade C or D esophagitis, and PPI-responsive symptoms with troublesome regurgitation as the main problem. The American College of Gastroenterology suggests it for patients with troublesome regurgitation or heartburn who don't want surgery and don't have severe esophagitis or a hernia over two centimeters. Symptom improvement is good for the first one to two years, but reoperation and return to PPI rise over five years. Combining a laparoscopic hernia repair with a later transoral fundoplication extends it to patients with larger hernias.
Applying the rules to him settles the choice. He has normal motility, proven reflux, regurgitation as the main complaint, a body mass index of twenty-nine, no Barrett, no severe esophagitis, and a two-and-a-half-centimeter hernia. The transoral fundoplication is out, because his hernia is over two centimeters. The magnetic ring fits every criterion, and so does a Nissen. He chooses the magnetic ring, because he wants to keep his ability to belch. Six months later his regurgitation is gone and he's off his PPI.
Weight would have changed the decision. A patient with the same reflux and a body mass index of forty is at higher risk of fundoplication failure, since a body mass index over thirty-five predicts it, and is excluded from the magnetic ring. For that patient, the antireflux operation is Roux-en-Y gastric bypass. It controls reflux by diverting bile away from the esophagus and leaving a small gastric pouch with few acid-producing parietal cells, and it treats the obesity that drives the reflux. A sleeve gastrectomy is the wrong operation, because it causes or worsens reflux: the smaller stomach runs a higher pressure, the angle of His is lost, and the sling fibers at the junction are disrupted.
Other endoscopic treatments exist but aren't routine. Radiofrequency treatment of the junction was proposed to remodel the lining and reduce transient sphincter relaxations, but it gave only modest results against sham procedures, and American College of Gastroenterology guidance is that endoscopic antireflux procedures aren't routinely indicated. Injectable bulking agents are no longer marketed. Antireflux mucosectomy, which removes mucosa at the cardia so the scar rebuilds the flap valve, has good results in Asian series and is being studied in the United States. An implant that anchors the sphincter in the abdomen and recreates the angle of His with a fundus pouch has strong results in European series and is under study in the United States.
Here are the traps the boards set in these patients.
In the refractory workup, escalating the dose without asking about timing misses the one-in-eight who simply take it wrong. Skipping biopsies because a prior endoscopy was normal misses eosinophilic esophagitis. Testing on PPI when reflux was never proven hides the diagnosis, and testing off PPI when it was proven answers the wrong question.
In reading the study, calling normal acid exposure with a positive symptom association functional heartburn mislabels reflux hypersensitivity, which still gets acid suppression. Escalating acid suppression in functional heartburn, or sending it to surgery, treats reflux that isn't there. Missing rumination and supragastric belching sends behavioral disorders down the reflux pathway. And putting a patient with cough on a lifelong PPI on the strength of a laryngoscopy relies on findings most healthy people have.
In surgical selection, operating for PPI failure without objective reflux fails. Telling a PPI responder that surgery works better than medicine misstates the evidence. Skipping manometry misses achalasia and weak motility, and doing a Nissen with weak peristalsis or scleroderma causes severe dysphagia.
In the alternatives, placing a magnetic ring with a hernia over three centimeters, a body mass index over thirty-five, Barrett, or severe esophagitis breaks its exclusions. Doing a transoral fundoplication with a hernia over two centimeters breaks its criteria. Scoping first when a wrap fails, instead of a barium swallow, misses the geometry. And recommending a sleeve gastrectomy to an obese patient with reflux makes the reflux worse.
So, start to finish.
Most refractory heartburn isn't refractory acid reflux. Fix the PPI timing first, then intensify with twice-daily dosing, a more potent PPI, or vonoprazan. Scope with biopsies from two levels, even after a normal endoscopy.
Then measure reflux: off PPI with a wireless capsule if reflux was never proven, on PPI with impedance if it was. Acid exposure over six percent is reflux disease, under four argues against it, and four to six needs supporting evidence. With normal acid exposure, a positive symptom association is reflux hypersensitivity, treated with acid suppression plus a neuromodulator, and a negative one is functional heartburn, treated with a neuromodulator alone and never with surgery. Baclofen and alginates help proven reflux that persists on a PPI, and extraesophageal symptoms need objective testing first.
Surgery requires objective reflux, and its workup is endoscopy with hernia size, manometry, and pH testing when reflux isn't already proven. Its main advantage over a PPI is regurgitation. Match the wrap to motility: Nissen for normal peristalsis, Toupet for weak peristalsis, Dor after a Heller myotomy, and no full wrap in scleroderma.
A magnetic ring is excluded by a hernia over three centimeters, a body mass index over thirty-five, Barrett, severe esophagitis, or absent peristalsis. Transoral fundoplication needs a hernia under two centimeters. For morbid obesity, the antireflux operation is gastric bypass, never a sleeve.
Episode three is the patient whose reflux has caused food to stick, and how to tell a peptic stricture from a Schatzki ring, because they're dilated differently.